article
Inside AACR: DARPins take aim at hard-to-treat tumours
Amelie Croset of Molecular Partners breaks down the DARPin developments featured at AACR 2025 – from targeted radiopharmaceuticals to precision-engineered immune cell engagers.
List view / Grid view
Translational Science
news
Why PARP inhibitors fail: key role of the CST complex in BRCA1-deficient cancers
Researchers from UT Health San Antonio have identified the CST protein complex as a key driver of resistance to PARP inhibitors in BRCA1-deficient cancers – which could lead to more personalised treatments for breast, ovarian and prostate cancer patients.
news
New drug combo targets colorectal cancer mutation
Dr Justin Taylor of Sylvester Comprehensive Cancer Center has identified a promising drug combination that shrinks colorectal tumours in preclinical models.
news
$250K grant fuels development of new type 1 diabetes therapy
Researchers at Washington University in St. Louis have received a $250,000 grant from the Critical Path Institute’s Translational Therapeutics Accelerator (TRxA) to develop a novel CD22 bidentate therapeutic for type 1 diabetes to support formulation and new preclinical studies.
news
‘Delete-to-recruit’: new gene-editing method targets sickle cell
Researchers have developed a novel gene therapy approach that reactivates dormant genes by repositioning them closer to genetic switches called enhancers - showing promise for treating blood disorders like sickle cell disease.
news
Experimental drug targets gene driving severe seizures in children
Researchers at the Fralin Biomedical Research Institute are developing a targeted KCNT1 inhibitor that has shown early promise in reducing seizures in preclinical models.
news
Scientists grow 3D brain that mimics the real thing
Researchers at POSTECH have developed a new 3D brain model that closely mimics the structure and function of human brain tissue – marking a major advance in early disease detection.
news
New partnership targets CNS symptoms in ultra-rare diseases
Chiesi Group and Key2Brain have signed a global license agreement to develop two blood-brain barrier-crossing enzyme replacement therapies for alpha-mannosidosis and Krabbe disease – with the aim to help patients with limited treatment options.
news
AI platform detects new drug targets in minutes
Fauna Bio has launched Fauna Brain™, a powerful new AI platform that leverages the company’s expertise in comparative genomics to accelerate drug target discovery.
podcasts
Translating Promising Drug Candidates from Preclinical Screening to Clinical Trials
How do new cancer drugs make it to patients? This episode uncovers the challenges, successes, and AI advancements driving oncology treatments from preclinical screening to clinical trials.
news
Turning AI into a biological design engine
DenovAI has unveiled a powerful AI-driven protein design platform capable of creating new, functional synthetic proteins from scratch - marking a big step forward for drug discovery.
news
New nanoparticle enhances cancer drug penetration
Researchers at Southern Medical University have developed a self-propelled ferroptosis nanoinducer that penetrates deeper into tumour tissues - offering a new strategy for safer and more effective cancer treatment.
news
New polymer boosts mRNA vaccine safety
A new material developed at Cornell University offers a more effective way to deliver mRNA vaccines by replacing polyethylene glycol (PEG) with a water-loving polymer poly(carboxybetaine) (PCB).
news
Scientists discover enzymes that redefine glycan pathways
Researchers at Tokyo University of Science have identified three new enzyme families that degrade the complex bacterial carbohydrate β-1,2-glucan – offering new opportunities for enzyme engineering.
news
Dual-action therapy clears MDR bacteria in preclinical models
Centauri Therapeutics has published data showing that CTX-09’s ability effectively clears drug-resistant Gram-negative bacteria through a novel dual mechanism, marking a promising development for new infection therapies.
